OUTLOOK THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$4.10 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-18.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-18
- OUTLOOK THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$8.20M.
- OUTLOOK THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-06-30 was -$376.96K.
- OUTLOOK THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-03-31 was -$343.58K.
- OUTLOOK THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-12-31 was -$162.35K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month |
|---|---|---|---|
| 2026-06-30 | -$8.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-18 | -$4.10M 10-Q · filed 2026-08-18 | |
| 2026-03-31 | $4.10M 10-Q · filed 2026-05-15 | ||
| 2022-06-30 | -$376.96K 10-Q · filed 2022-08-10 | -$720.55K derived: sum of 2 quarters · filed 2022-08-10 | -$882.90K 10-Q · filed 2022-08-10 |
| 2022-03-31 | -$343.58K 10-Q · filed 2022-05-13 | -$505.94K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | -$162.35K 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |